AbbVie Rinvoq Settlement: Generic Challenge Averted | Fierce Pharma

by Archynetys Health Desk

In late August, AbbVie served up a second helping of positive phase 3 results for Rinvoq in the follicle-attacking hairloss disease alopecia areata.

Related Posts

Leave a Comment